ZURICH (Reuters) – Swiss drugs regulator Swissmedic said on Monday it approved Ronapreve, an antibody treatment jointly developed by Roche and Regeneron, to treat COVID-19 patients.
“In this procedure, no data on efficacy against the Omicron variant were submitted,” Swissmedic said in a statement.
The antibody treatment was already authorised for prescription in Switzerland under COVID-19 Ordinance 3 since April 15, Swissmedic said.
(Reporting by Silke Koltrowitz, Editing by Miranda Murray)
